↓ Skip to main content

Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma

Overview of attention for article published in Inflammation and Regeneration, March 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
20 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma
Published in
Inflammation and Regeneration, March 2018
DOI 10.1186/s41232-018-0060-2
Pubmed ID
Authors

Nanumi Han, Muhammad Baghdadi, Kozo Ishikawa, Hiraku Endo, Takuto Kobayashi, Haruka Wada, Keisuke Imafuku, Hiroo Hata, Ken-ichiro Seino

Abstract

Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death, which necessitates the identification of related resistance mechanisms.IL-34 is a cytokine that controls the biology of myeloid cell lineage through binding to CSF-1R. IL-34 is importantly involved in the pathogenesis of various diseases. In cancer, the expression of IL-34 has been suggested to associate with tumor growth, metastasis, angiogenesis, and therapeutic resistance such as in lung cancers and malignant pleural mesotheliomas. In this study, we evaluate the possible involvement of IL-34 in immunotherapeutic resistance. Melanoma resection species were obtained from a patient who developed a refractory melanoma against immunotherapy with Nivolumab, and stained with anti-IL-34, anti-melanoma antigens and anti-CD163 antibody. Staining of these markers was compared between primary or metastatic refractory melanoma tissues. Immunohistochemistry staining of melanoma tissues showed an enhanced expression of IL-34 in metastatic refractory melanoma compared to primary melanoma tissues, which correlates with increased frequencies of CD163+macrophages. We introduce for the first time a clinical case of a patient with metastatic refractory melanoma that acquired resistance to anti-PD-1 immunotherapy, showing an enhanced expression of IL-34 in refractory melanoma tissues.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 4 20%
Student > Master 4 20%
Researcher 3 15%
Student > Bachelor 1 5%
Student > Doctoral Student 1 5%
Other 2 10%
Unknown 5 25%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 30%
Immunology and Microbiology 6 30%
Medicine and Dentistry 2 10%
Agricultural and Biological Sciences 1 5%
Unknown 5 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2018.
All research outputs
#7,919,956
of 12,620,777 outputs
Outputs from Inflammation and Regeneration
#48
of 88 outputs
Outputs of similar age
#161,123
of 272,287 outputs
Outputs of similar age from Inflammation and Regeneration
#1
of 1 outputs
Altmetric has tracked 12,620,777 research outputs across all sources so far. This one is in the 23rd percentile – i.e., 23% of other outputs scored the same or lower than it.
So far Altmetric has tracked 88 research outputs from this source. They receive a mean Attention Score of 2.0. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 272,287 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them